Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Volker Limmroth

Showing results (11-20 of 87) with videos related to

Pageof 9
Sort By:
Journal of the Neurological Sciences|March 29, 2005
High-dose, frequently administered interferon betaVolker Limmroth, Norman Putzki
Current Pain and Headache Reports|March 3, 2012
Oral triptans in the preventive management of cluster headacheLutz Pageler, Volker Limmroth
Expert Opinion on Drug Delivery|September 27, 2014
Single-use autoinjector for once-weekly intramuscular injection of IFNβ-1aVolker Limmroth, Kathrin Gerbershagen
European Neurology|August 6, 2008
Pain therapy in german neurology. Structures and standards of evaluationKathrin Gerbershagen, Volker Limmroth
Medizinische Monatsschrift Fur Pharmazeuten|January 1, 2004
[Multiple sclerosis. Current aspects of the disease and treatment]Matthias Maschke, Volker Limmroth
Multiple Sclerosis and Related Disorders|March 26, 2018
Letter to the editor to the paper: "Acute and long-term effects of fingolimod on heart rhythm and heart rate variability in patients with multiple sclerosis"Tjalf Ziemssen, Volker Limmroth
The Lancet. Neurology|July 21, 2004
Medication-overuse headache: a worldwide problemHans-Christoph Diener, Volker Limmroth
Current Pain and Headache Reports|November 12, 2005
Medication-overuse headacheLutz Pageler, Irini Savidou, Volker Limmroth
Handbook of Clinical Neurology|September 7, 2010
Headache attributed to a substance or its withdrawalHans-Christoph Diener, Zaza Katsarava, Volker Limmroth
Therapeutic Advances in Neurological Disorders|October 20, 2011
The interferon beta therapies for treatment of relapsing-remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combinationVolker Limmroth, Norman Putzki, Norman J Kachuck
Pageof 9

Showing results (11-20 of 87) with videos related to

Sort By:
Pageof 9
Journal of the Neurological Sciences|March 29, 2005
High-dose, frequently administered interferon betaVolker Limmroth, Norman Putzki
Current Pain and Headache Reports|March 3, 2012
Oral triptans in the preventive management of cluster headacheLutz Pageler, Volker Limmroth
Expert Opinion on Drug Delivery|September 27, 2014
Single-use autoinjector for once-weekly intramuscular injection of IFNβ-1aVolker Limmroth, Kathrin Gerbershagen
European Neurology|August 6, 2008
Pain therapy in german neurology. Structures and standards of evaluationKathrin Gerbershagen, Volker Limmroth
Medizinische Monatsschrift Fur Pharmazeuten|January 1, 2004
[Multiple sclerosis. Current aspects of the disease and treatment]Matthias Maschke, Volker Limmroth
Multiple Sclerosis and Related Disorders|March 26, 2018
Letter to the editor to the paper: "Acute and long-term effects of fingolimod on heart rhythm and heart rate variability in patients with multiple sclerosis"Tjalf Ziemssen, Volker Limmroth
The Lancet. Neurology|July 21, 2004
Medication-overuse headache: a worldwide problemHans-Christoph Diener, Volker Limmroth
Current Pain and Headache Reports|November 12, 2005
Medication-overuse headacheLutz Pageler, Irini Savidou, Volker Limmroth
Handbook of Clinical Neurology|September 7, 2010
Headache attributed to a substance or its withdrawalHans-Christoph Diener, Zaza Katsarava, Volker Limmroth
Therapeutic Advances in Neurological Disorders|October 20, 2011
The interferon beta therapies for treatment of relapsing-remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combinationVolker Limmroth, Norman Putzki, Norman J Kachuck
Pageof 9